249 related articles for article (PubMed ID: 16690963)
21. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
[TBL] [Abstract][Full Text] [Related]
22. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
Moros A; Bustany S; Cahu J; Saborit-Villarroya I; Martínez A; Colomer D; Sola B; Roué G
Clin Cancer Res; 2014 Jan; 20(2):393-403. PubMed ID: 24178620
[TBL] [Abstract][Full Text] [Related]
23. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.
Chaturvedi NK; Hatch ND; Sutton GL; Kling M; Vose JM; Joshi SS
Leuk Lymphoma; 2019 May; 60(5):1214-1223. PubMed ID: 30424705
[TBL] [Abstract][Full Text] [Related]
24. No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.
Vogt N; Abramov D; Koch K; Masqué-Soler N; Szczepanowski M; Klapper W
Leuk Lymphoma; 2015 Jul; 56(7):2134-40. PubMed ID: 25315075
[TBL] [Abstract][Full Text] [Related]
25. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract][Full Text] [Related]
26. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.
Klier M; Anastasov N; Hermann A; Meindl T; Angermeier D; Raffeld M; Fend F; Quintanilla-Martinez L
Leukemia; 2008 Nov; 22(11):2097-105. PubMed ID: 18685613
[TBL] [Abstract][Full Text] [Related]
27. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
[TBL] [Abstract][Full Text] [Related]
28. Detection of cyclin D1 overexpression by real-time reverse-transcriptase-mediated quantitative polymerase chain reaction for the diagnosis of mantle cell lymphoma.
Suzuki R; Takemura K; Tsutsumi M; Nakamura S; Hamajima N; Seto M
Am J Pathol; 2001 Aug; 159(2):425-9. PubMed ID: 11485900
[TBL] [Abstract][Full Text] [Related]
29. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition.
Guiley KZ; Stevenson JW; Lou K; Barkovich KJ; Kumarasamy V; Wijeratne TU; Bunch KL; Tripathi S; Knudsen ES; Witkiewicz AK; Shokat KM; Rubin SM
Science; 2019 Dec; 366(6471):. PubMed ID: 31831640
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
31. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
32. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.
Wiestner A; Tehrani M; Chiorazzi M; Wright G; Gibellini F; Nakayama K; Liu H; Rosenwald A; Muller-Hermelink HK; Ott G; Chan WC; Greiner TC; Weisenburger DD; Vose J; Armitage JO; Gascoyne RD; Connors JM; Campo E; Montserrat E; Bosch F; Smeland EB; Kvaloy S; Holte H; Delabie J; Fisher RI; Grogan TM; Miller TP; Wilson WH; Jaffe ES; Staudt LM
Blood; 2007 Jun; 109(11):4599-606. PubMed ID: 17299095
[TBL] [Abstract][Full Text] [Related]
33. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene.
Lu F; Gladden AB; Diehl JA
Cancer Res; 2003 Nov; 63(21):7056-61. PubMed ID: 14612495
[TBL] [Abstract][Full Text] [Related]
34. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.
Fu K; Weisenburger DD; Greiner TC; Dave S; Wright G; Rosenwald A; Chiorazzi M; Iqbal J; Gesk S; Siebert R; De Jong D; Jaffe ES; Wilson WH; Delabie J; Ott G; Dave BJ; Sanger WG; Smith LM; Rimsza L; Braziel RM; Müller-Hermelink HK; Campo E; Gascoyne RD; Staudt LM; Chan WC;
Blood; 2005 Dec; 106(13):4315-21. PubMed ID: 16123218
[TBL] [Abstract][Full Text] [Related]
35. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis.
Quintanilla-Martinez L; Davies-Hill T; Fend F; Calzada-Wack J; Sorbara L; Campo E; Jaffe ES; Raffeld M
Blood; 2003 Apr; 101(8):3181-7. PubMed ID: 12515730
[TBL] [Abstract][Full Text] [Related]
36. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1.
Sander B; Flygare J; Porwit-Macdonald A; Smith CI; Emanuelsson E; Kimby E; Liden J; Christensson B
Int J Cancer; 2005 Nov; 117(3):418-30. PubMed ID: 15900590
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
38. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.
Grillo M; Bott MJ; Khandke N; McGinnis JP; Miranda M; Meyyappan M; Rosfjord EC; Rabindran SK
Breast Cancer Res Treat; 2006 Jan; 95(2):185-94. PubMed ID: 16319987
[TBL] [Abstract][Full Text] [Related]
39. Characterization of 4 mantle cell lymphoma cell lines.
Amin HM; McDonnell TJ; Medeiros LJ; Rassidakis GZ; Leventaki V; O'Connor SL; Keating MJ; Lai R
Arch Pathol Lab Med; 2003 Apr; 127(4):424-31. PubMed ID: 12683869
[TBL] [Abstract][Full Text] [Related]
40. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
Guidoboni M; Zancai P; Cariati R; Rizzo S; Dal Col J; Pavan A; Gloghini A; Spina M; Cuneo A; Pomponi F; Bononi A; Doglioni C; Maestro R; Carbone A; Boiocchi M; Dolcetti R
Cancer Res; 2005 Jan; 65(2):587-95. PubMed ID: 15695403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
